Atyr PHARMA (NASDAQ:ATYR) Announces Quarterly Earnings Results

Atyr PHARMA (NASDAQ:ATYR) issued its earnings results on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05, Zacks reports.

Atyr PHARMA Price Performance

NASDAQ ATYR traded up $0.44 on Thursday, hitting $3.99. The stock had a trading volume of 1,787,852 shares, compared to its average volume of 1,285,216. The firm has a 50-day moving average of $3.65 and a 200-day moving average of $3.04. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. Atyr PHARMA has a 52-week low of $1.42 and a 52-week high of $4.66. The company has a market capitalization of $334.93 million, a price-to-earnings ratio of -4.24 and a beta of 0.98.

Wall Street Analysts Forecast Growth

ATYR has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a report on Tuesday, December 10th. Cantor Fitzgerald initiated coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They issued an “overweight” rating for the company. Leerink Partners assumed coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price target on the stock. Finally, Leerink Partnrs upgraded shares of Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $18.60.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.